-
公开(公告)号：US11773126B2
公开(公告)日：2023-10-03
申请号：US17446007
申请日：2021-08-26
发明人： Leonid Beigelman , Jerome Deval , Marija Prhavc
摘要： Disclosed herein are compounds of the Formula (I) and pharmaceutically acceptable salts thereof: (I) where the variables in Formula (I) are described herein. Methods of synthesizing such compounds and methods of using them to treat diseases and/or conditions such as a Picornaviridae, Flaviviridae, Filoviridae, Pneumoviridae and/or Coronaviridae viral infections are also disclosed.
-
公开(公告)号：US20230302119A1
公开(公告)日：2023-09-28
申请号：US18004343
申请日：2021-07-05
IPC分类号： A61K39/215 , C12N15/86
CPC分类号： A61K39/215 , C12N15/86 , A61K2039/53
摘要： The present invention provides stabilized recombinant pre-fusion SARS CoV0-2 S proteins, nucleic acids molecules encoding the SARS CoV-2 S proteins and uses thereof.
-
公开(公告)号：US11707440B2
公开(公告)日：2023-07-25
申请号：US16956403
申请日：2018-12-18
发明人： Wayne Drevets , Honglan Li , David Wood Hough , Jaskaran Singh , Ewa Wajs
IPC分类号： A61K31/135 , A61P25/24 , A61K9/00
CPC分类号： A61K31/135 , A61K9/0043 , A61K9/0053 , A61P25/24
摘要： The present invention provides methods of maintaining stable remission or stable response achieved by a patient with depression following administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuing administration of a therapeutically effective amount of esketamine for at least five months during a subsequent administration phase. The present invention also provides methods for the long term treatment of depression in a patient, comprising administering to the patient in need of the treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some embodiments, the depression is major depressive disorder or treatment resistant depression.
-
公开(公告)号：US11684576B2
公开(公告)日：2023-06-27
申请号：US16785011
申请日：2020-02-07
发明人： Andrea Pfeifer , Andreas Muhs , Maria Pihlgren Bosch , Marija Vukicevic Verhille , Nicolas Piot , Saroj Raj Ghimire , Elizabeth Anne Ramsburg , Donata De Marco , Charlotte Sadaka
CPC分类号： A61K9/1271 , A61K39/0007 , A61P25/28 , A61K2039/545 , A61K2039/55516 , A61K2039/55555 , A61K2039/55561 , A61K2039/55572 , A61K2039/6018 , A61K2039/627
摘要： Methods for inducing anti-phosphorylated Tau antibodies without inducing a severe adverse event in humans are described. The methods include administering to the subject an effective amount of liposomes including a toll-like receptor 4 agonist and a Tau phosphopeptide presented on the surface of the liposome.
-
15.发明公开公开(公告)号：US20230190926A1
公开(公告)日：2023-06-22
申请号：US17938454
申请日：2022-10-06
发明人： Jeroen GEURTSEN , Pieter Jan BURGHOUT , Eveline Marleen WEERDENBURG , Jan Theunis POOLMAN , Kellen Cristhina FAE , Patricia IBARRA YON , Darren Robert ABBANAT , Stefan Jochen KEMMLER , Michael Thomas KOWARIK , Manuela MALLY , Veronica GAMBILLARA FONCK , Martin Edward BRAUN , Maria Paula CARRANZA SANDMEIER
IPC分类号： A61K39/385 , A61K39/108 , A61K39/02 , A61K47/64 , A61K39/085 , A61K39/095 , A61K39/102 , A61K39/09 , A61K39/104
CPC分类号： A61K39/385 , A61K39/0258 , A61K39/107 , A61K47/646 , A61K39/085 , A61K39/095 , A61K39/102 , A61K39/092 , A61K39/104 , A61K2039/6037
摘要： Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli. (ExPEC).
-
公开(公告)号：US11649283B2
公开(公告)日：2023-05-16
申请号：US15488351
申请日：2017-04-14
发明人： Michael Molloy , Jay Rothstein , Dov Pechenick , Linda Snyder , Gordon Powers
IPC分类号： C07K16/28 , A61K39/395 , A61P17/06 , A61P1/16 , A61P37/06 , A61P19/02 , A61P13/12 , A61P1/00 , A61K45/06 , A61K38/17 , A61K39/00
CPC分类号： C07K16/2803 , A61K38/17 , A61K39/395 , A61K39/3955 , A61K45/06 , A61P1/00 , A61P1/16 , A61P13/12 , A61P17/06 , A61P19/02 , A61P37/06 , C07K16/2827 , C07K16/2896 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/522 , C07K2317/53 , C07K2317/565 , C07K2317/73 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92
摘要： The invention provides antagonistic and agonistic anti-human VISTA antibodies and antibody fragments. These antagonist antibodies and antibody fragments may be used to inhibit or block VISTA's suppressive effects on T cell immunity and thereby promote T cell immunity. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These antagonist antibodies and antibody fragments are especially useful in the treatment of cancer and infectious conditions. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.
-
公开(公告)号：US11602599B2
公开(公告)日：2023-03-14
申请号：US16716913
申请日：2019-12-17
IPC分类号： A61M5/32
摘要： An accessory for an injection device having a needle cap. The accessory comprises a body portion comprising a recess adapted to receive the injection device and a cover coupled to the body portion. The cover is pivotally moveable between an open position in which the recess is exposed to receive the injection device, and a closed position in which the cover at least partially closes the recess to hold the injection device in the body portion. The accessory further comprises a cap remover comprising a grip adapted to hold the needle cap. The cap remover is moveable with respect to the body portion.
-
公开(公告)号：US11555205B2
公开(公告)日：2023-01-17
申请号：US16703359
申请日：2019-12-04
IPC分类号： C12N15/86 , C07K16/32 , A61K48/00 , C07K14/005 , C12P21/00
摘要： The present disclosure generally relates to viral-based expression systems suitable for the production of molecule of interests in recombinant host cells. The disclosure particularly relates to nucleic acid constructs, such as expression vectors, containing a modified arterivirus genome or replicon RNA in which at least some of its original viral sequence has been deleted. Also included in the disclosure are viral-based expression vectors including one or more expression cassettes encoding heterologous polypeptides. In some embodiments, the expression cassettes are configured and positioned at defined locations on the viral genome so as to enable expression of the heterologous polypeptides in a tunable manner.
-
公开(公告)号：US20220409583A1
公开(公告)日：2022-12-29
申请号：US17777019
申请日：2020-11-13
发明人： Olivia Gabriella M. GOETHALS , Bart Rudolf Romanie KESTELEYN , Bart Henri Theresia STOOPS , Jean-François BONFANTI , Tim Hugo Maria JONCKERS , Marnix VAN LOOCK , Suzanne KAPTEIN , Johan NEYTS
IPC分类号： A61K31/4045 , A61P31/14
摘要： The present invention relates to the use of substituted indole derivatives and substituted indoline derivatives in the manufacture of a medicament for the treatment of dengue disease in an individual infected by dengue virus or the prevention of dengue disease in an individual at risk of being infected by Dengue virus. The invention further provides a method for the treatment or the prevention of dengue in an individual at risk of being infected by Dengue virus.
-
公开(公告)号：US20220361758A1
公开(公告)日：2022-11-17
申请号：US17763033
申请日：2020-09-24
发明人： Francesco N. ALBERTINI , Gregory J. BAKOS , Jeffrey DANIEL , Anthony R. DIUBALDI , James A. FLEMING , Jason L. HARRIS , Kevin L. HOUSER , Emma Louise HUBERT , Michael HUTCHINSON , David KALIKHMAN , Monica A. KAPIL , Wouter Jacques Noel LEQUIEU , David RAMOS , Ian SCRIMGEOUR , Frederick E. SHELTON, IV , Jaskaran SINGH , Steven M. VESOLE , Jingli WANG , Hong YAN
摘要： In general, drug administration devices configured to communicate with networks and external devices are provided. In an exemplary embodiment, a drug administration device is configured to adjust an operational parameter of the drug administration device based on a data packet formed from drug administration data ancillary data received from networks and/or external devices. In another example embodiment, a drug administration device is configured to scan for and establish communications with at least one external device. In another example embodiment, a method includes assessing whether to update a control program on a drug administration device from a network or external device. In another example embodiment, a system includes a first drug administration device configured to communicate with a second drug administration device to optimize a drug treatment.
-
-
-
-
-
-
-
-
-
搜索结果
275 条记录 (耗时 0.03 秒)
